secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001558370-24-009419
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock presents SRK-439 preclinical data showing lean mass preservation and initiates Phase 2 EMBRAZE trial
--------------------------------------------------------------------------------

- Preclinical DIO mouse study: SRK-439 with semaglutide preserved lean mass (26.4g vs 22.3g at 4 weeks, p<0.001) and increased relative lean mass (65.8%) after semaglutide withdrawal vs control (57.1%).
- SRK-439 attenuated fat mass rebound after semaglutide withdrawal: relative fat mass 18.0% vs 28.7% (p<0.01) and reduced inguinal and epididymal adipose weights.
- First participants dosed in Phase 2 EMBRAZE proof-of-concept trial of apitegromab in obesity patients on GLP-1 RA background therapy to assess lean muscle preservation.
- Data presented at ADA 84th Scientific Sessions on June 23, 2024, supporting SRK-439's potential for healthier weight management and long-term metabolic benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/0001558370-24-009419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024009419/srrk-20240624x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer